Back
Evaluation of Safety and Efficacy of Glaritus® versus Lantus® in Combination with Insulin Lispro among Adults with Type 1 Diabetes Mellitus-Phase IV Study
Gaurav Puppalwar, Sandesh Sawant, Bhimsen Silgiri, Kirti Shukla, Hanmant Barkate
Open J. Endocr. Metab. Dis. Vol.7 No.4, April 30, 2017  DOI: 10.4236/ojemd.2017.74011
       (PDF  907K)     HTML      XML
Immunogenicity, Safety and Efficacy Comparison of Wockhardt’s Biosimilar Insulin Glargine—Glaritus® with Reference Product— Lantus®: Study Protocol & Early Data Trends
S. K. Sharma, A. K. Ajmani, P. Khosla, P. Mukhopadhyay, G. Bhatia, K. G. Prakash, G. Chhaya, P. D. Supe, V. Pavithran, H. Bora, R. Jain, S. Ingole, A. Shah
Open J. Endocr. Metab. Dis. Vol.8 No.8, August 30, 2018  DOI: 10.4236/ojemd.2018.88016
       (PDF  265K)     HTML      XML
Assessing insulin effectiveness at the end of the day: Once-daily versus twice-daily insulin glargine injection
Mark R. Burge, Eric R. Schroeder, Stephen Mitchell
J. Diabetes Mellit. Vol.2 No.2, May 25, 2012  DOI: 10.4236/jdm.2012.22032
       (PDF  301K)     HTML      XML
Iowa medicaid 2: lapse of glycemic control on abrupt transition from insulin glargine to insulin detemir in type 2 diabetes mellitus
Udaya Kabadi
J. Diabetes Mellit. Vol.1 No.4, November 08, 2011  DOI: 10.4236/jdm.2011.14017
       (PDF  82K)     HTML     
Efficacy and Safety of Patient-Led Dosage Adjustments of Insulin Glargine: A Preliminary Report of Basal-Supported Oral Therapy for Japanese Type 2 Diabetes Patients
Shuhei Nakanishi, Mitsunobu Kubota, Rui Kishimoto
J. Diabetes Mellit. Vol.4 No.2, April 21, 2014  DOI: 10.4236/jdm.2014.42014
       (PDF  363K)     HTML     
 
 
Top